Trifluoperazine does not affect doxorubicin cardiotoxicity in the rat.
Sprague Dawley rats received doxorubicin (DXR) at a dose of 3 mg/kg i.v. every third day for a total of three administrations, according to an acute and delayed cardiotoxicity experimental model previously described. DXR was found to induce significant ECG alterations (Qat and Sat prolongation) and typical morphologic lesions in the left ventricle. Trifluoperazine (TFP), administered at the doses of 0.2 of 2 mg/kg i.p., 5 days a week for 4 weeks, starting 1 day before DXR, was ineffective in preventing the electrocardiographic and morphologic alterations induced by DXR.
Villani
F
F
Servizio di Fisiopatologia Cardiorespiratoria, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
Monti
E
E
Piccinini
F
F
Favalli
L
L
Rozza Dionigi
A
A
Lanza
E
E
Poggi
P
P
D000818:Animals; D004317:Doxorubicin / Q000633:toxicity*; D005260:Female; D006321:Heart / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology*; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D014268:Trifluoperazine / Q000494:pharmacology*
D014268:Trifluoperazine; D004317:Doxorubicin